Congratulations to our portfolio company, Syntis Bio, on their $38M Series A round!

Our Boston-based portfolio company, Syntis Bio, recently announced their $38M Series A round to help target obesity and rare diseases. Syntis CEO and Founder, Rahul Dhanda was recently featured in Endpoints to discuss the raise.